CZ20032872A3 - Peptický ligand, který váže receptor somatostatinu - Google Patents

Peptický ligand, který váže receptor somatostatinu Download PDF

Info

Publication number
CZ20032872A3
CZ20032872A3 CZ20032872A CZ20032872A CZ20032872A3 CZ 20032872 A3 CZ20032872 A3 CZ 20032872A3 CZ 20032872 A CZ20032872 A CZ 20032872A CZ 20032872 A CZ20032872 A CZ 20032872A CZ 20032872 A3 CZ20032872 A3 CZ 20032872A3
Authority
CZ
Czechia
Prior art keywords
peptide ligand
peptide
carbohydrate
toc
ligand
Prior art date
Application number
CZ20032872A
Other languages
Czech (cs)
English (en)
Inventor
Hans Jurgen Wester
Margret Schottelius
Markus Schwaiger
Original Assignee
Mallinckrodt Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc. filed Critical Mallinckrodt Inc.
Publication of CZ20032872A3 publication Critical patent/CZ20032872A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CZ20032872A 2001-04-23 2002-04-23 Peptický ligand, který váže receptor somatostatinu CZ20032872A3 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01201466 2001-04-23

Publications (1)

Publication Number Publication Date
CZ20032872A3 true CZ20032872A3 (cs) 2005-01-12

Family

ID=8180193

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20032872A CZ20032872A3 (cs) 2001-04-23 2002-04-23 Peptický ligand, který váže receptor somatostatinu

Country Status (11)

Country Link
US (2) US7589061B2 (https=)
EP (1) EP1381396B1 (https=)
JP (3) JP5398945B2 (https=)
AT (1) ATE427125T1 (https=)
AU (1) AU2002254691B8 (https=)
BR (1) BR0209074A (https=)
CA (1) CA2443273C (https=)
CZ (1) CZ20032872A3 (https=)
DE (1) DE60231801D1 (https=)
HU (1) HU228811B1 (https=)
WO (1) WO2002085418A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157086A0 (en) * 2003-07-24 2004-02-08 Guy Patchornik Multivalent ligand complexes
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
CN102253174A (zh) * 2011-04-27 2011-11-23 江苏省原子医学研究所 一种受体显像剂标记的化学动力学研究的方法
AU2012302636B2 (en) * 2011-09-04 2016-09-15 Glytech, Inc. Glycosylated polypeptide and drug composition containing said polypeptide
BR112014004936A2 (pt) * 2011-09-04 2017-04-04 Glytech Inc polipeptídeo glicosilado e composição de drogas contendo referido polipeptídeo
PL3152226T3 (pl) * 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania
HRP20231458T1 (hr) 2017-01-12 2024-05-10 Radiomedix Inc. Liječenje stanica raka koje prekomjerno eksprimiraju receptore za somatostatin primjenom derivata oktreotida keliranih sa radioizotopima
CN113747927B (zh) * 2019-02-14 2024-10-18 德国癌症研究中心 包含淀粉酶可切割接头的前列腺特异性膜抗原(psma)配体
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194729C (nl) * 1986-10-13 2003-01-07 Novartis Ag Werkwijze voor de bereiding van peptidealcoholen via vaste fase.
JP2544159B2 (ja) 1987-10-07 1996-10-16 ハウス食品株式会社 連続蒸煮装置
MY106120A (en) 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5590656A (en) * 1992-09-15 1997-01-07 The Ohio State University Research Foundation Application of peptide/cell receptor kinetics utilizing radiolabeled somatostatin congeners in the in situ, in vivo detection and differentiation of neoplastic tissue
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
EP0799050B1 (en) 1994-12-07 2004-08-11 Neorx Corporation Radiolabeled annexin-galactose cluster conjugates
JPH10512852A (ja) 1994-12-07 1998-12-08 ネオルクス コーポレイション 放射性標識化アネキシン−ガラクトースクラスター複合体
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
AU1821397A (en) 1995-12-21 1997-11-07 Scripps Research Institute, The Targeted therapeutic or diagnostic agents and methods of making and using same
DE19654764A1 (de) 1996-12-30 1998-07-02 Boehringer Mannheim Gmbh Verfahren zur Herstellung eines Peptidgemisches
EP1068224B1 (en) 1998-03-31 2005-05-11 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19910419A1 (de) 1999-03-10 2000-09-21 Aventis Pharma Gmbh Zielzellspezifische, multivalente Proteine (MVP)

Also Published As

Publication number Publication date
HUP0303987A3 (en) 2010-03-29
WO2002085418A3 (en) 2003-09-12
US20090324497A1 (en) 2009-12-31
AU2002254691B8 (en) 2008-02-14
DE60231801D1 (de) 2009-05-14
JP2005514321A (ja) 2005-05-19
BR0209074A (pt) 2004-08-10
EP1381396A2 (en) 2004-01-21
US7589061B2 (en) 2009-09-15
US20060165593A1 (en) 2006-07-27
JP5398945B2 (ja) 2014-01-29
ATE427125T1 (de) 2009-04-15
CA2443273A1 (en) 2002-10-31
EP1381396B1 (en) 2009-04-01
US8575100B2 (en) 2013-11-05
HU228811B1 (hu) 2013-05-28
JP2010001313A (ja) 2010-01-07
CA2443273C (en) 2011-09-27
HUP0303987A2 (hu) 2004-03-01
AU2002254691B2 (en) 2007-06-14
JP2013100349A (ja) 2013-05-23
WO2002085418A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
US8575100B2 (en) Tc and Re labeled radioactive glycosylated octreotide derivatives
La Bella et al. In vitro and in vivo evaluation of a 99mTc (I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors
Decristoforo et al. Preparation, 99mTc-labeling, and in vitro characterization of HYNIC and N3S modified RC-160 and [Tyr3] octreotide
US7147838B2 (en) Gastrin receptor-avid peptide conjugates
JP6562838B2 (ja) Ｇｒｐｒ陽性ガンの診断画像及び治療適用のための放射標識したｇｒｐｒアンタゴニスト
Alves et al. Pyrazolyl conjugates of bombesin: a new tridentate ligand framework for the stabilization of fac-[M (CO) 3]+ moiety
US7060247B2 (en) Gastrin receptor-avid peptide conjugates
CA2485339C (en) Radiopharmaceutical formulations
Varvarigou et al. Synthesis, chemical, radiochemical and radiobiological evaluation of a new 99mTc-labelled bombesin-like peptide
AU2002254691A1 (en) Tc and Re labeler radioactive glycosylated octreotide derivatives
US20060067886A1 (en) Gastrin receptor-avid peptide conjugates
Kothari et al. 99mTc (CO) 3-VIP analogues: preparation and evaluation as tumor imaging agent
CN101272809B (zh) 生物素二氨基衍生物及其与大环螯合剂的缀合物
Chapleur et al. Toward imaging glycotools by click coupling
HK1125036B (en) Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents